Simon Tate
Director/Board Member chez ELIEM THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Simon Nicholas Tate is the founder of Convergence Pharmaceuticals Ltd.
He currently holds the position of Independent Director at Eliem Therapeutics, Inc. and is a Venture Partner at Bridge Valley Ventures LLP.
In the past, he has worked as a Managing Director at Intermediate Capital Group Plc, Non-Executive Director at Calchan Holdings Ltd.
and Calchan Ltd., Vice President & Head-Pain Therapeutic Area at Biogen, Inc., and VP-Pain & Epilepsy Discovery Performance Unit at GlaxoSmithKline, Inc. He graduated from the University of Dundee.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ELIEM THERAPEUTICS, INC.
-.--% | 18/05/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Simon Tate
| Sociétés | Poste | Début |
|---|---|---|
| ELIEM THERAPEUTICS, INC. | Director/Board Member | 01/02/2019 |
Bridge Valley Ventures LLP
 Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Private Equity Investor | - |
Anciens postes connus de Simon Tate
| Sociétés | Poste | Fin |
|---|---|---|
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Founder | 12/04/2018 |
| INTERMEDIATE CAPITAL GROUP PLC | Corporate Officer/Principal | - |
Calchan Ltd.
 Calchan Ltd. BiotechnologyHealth Technology Calchan Ltd. operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain. The company was founded by Brenda Elizabeth Reynolds in 2011 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
| BIOGEN INC. | Corporate Officer/Principal | - |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Formation de Simon Tate
| University Of Dundee | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BIOGEN INC. | Health Technology |
| INTERMEDIATE CAPITAL GROUP PLC | Finance |
| ELIEM THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
GlaxoSmithKline, Inc.
GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Health Technology |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Calchan Holdings Ltd.
 Calchan Holdings Ltd. Pharmaceuticals: MajorHealth Technology Calchan Holdings Ltd. develops novel oral state-dependent calcium channel modulators for chronic pain. The company was founded on February 25, 2011 and is headquartered in London, the United Kingdom. | Health Technology |
Calchan Ltd.
Calchan Ltd. BiotechnologyHealth Technology Calchan Ltd. operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain. The company was founded by Brenda Elizabeth Reynolds in 2011 and is headquartered in London, the United Kingdom. | Health Technology |
Bridge Valley Ventures LLP
Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Finance |
